The clinical pipeline for cell therapies has grown significantly, with growth in allogeneic therapies outpacing autologous approaches. While the late-stage cell therapy pipeline is relatively thin, the FDA predicts by 2025 they will approve 10 to 20 cell and gene therapy products annually. In a new article Back Bay considers the recent surge in VC investments and opportunities for advancement.

Read More